These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30386338)

  • 21. MicroRNA-130b regulates scleroderma fibrosis by targeting peroxisome proliferator-activated receptor γ.
    Luo H; Zhu H; Zhou B; Xiao X; Zuo X
    Mod Rheumatol; 2015 Jul; 25(4):595-602. PubMed ID: 25547017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sirt1 regulates canonical TGF-β signalling to control fibroblast activation and tissue fibrosis.
    Zerr P; Palumbo-Zerr K; Huang J; Tomcik M; Sumova B; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2016 Jan; 75(1):226-33. PubMed ID: 25180292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis.
    Svegliati S; Marrone G; Pezone A; Spadoni T; Grieco A; Moroncini G; Grieco D; Vinciguerra M; Agnese S; Jüngel A; Distler O; Musti AM; Gabrielli A; Avvedimento EV
    Sci Signal; 2014 Sep; 7(341):ra84. PubMed ID: 25185156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exosomes in Systemic Sclerosis: Messengers Between Immune, Vascular and Fibrotic Components?
    Colletti M; Galardi A; De Santis M; Guidelli GM; Di Giannatale A; Di Luigi L; Antinozzi C
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31487964
    [No Abstract]   [Full Text] [Related]  

  • 25. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.
    Distler O; Cozzio A
    Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of the activin A-ALK-Smad pathway in systemic sclerosis.
    Takagi K; Kawaguchi Y; Kawamoto M; Ota Y; Tochimoto A; Gono T; Katsumata Y; Takagi M; Hara M; Yamanaka H
    J Autoimmun; 2011 May; 36(3-4):181-8. PubMed ID: 21377836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-17 pathways in systemic sclerosis-associated fibrosis.
    Ahmed S; Misra DP; Agarwal V
    Rheumatol Int; 2019 Jul; 39(7):1135-1143. PubMed ID: 31073660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis.
    Leask A
    Pharmacol Res; 2011 Jun; 63(6):502-3. PubMed ID: 21315153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic mechanisms: An emerging role in pathogenesis and its therapeutic potential in systemic sclerosis.
    Luo Y; Wang Y; Shu Y; Lu Q; Xiao R
    Int J Biochem Cell Biol; 2015 Oct; 67():92-100. PubMed ID: 26043891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of hepatocyte growth factor receptor in scleroderma dermal fibroblasts is caused by autocrine transforming growth factor β signaling.
    Kajihara I; Jinnin M; Makino T; Masuguchi S; Sakai K; Fukushima S; Maruo K; Inoue Y; Ihn H
    Biosci Trends; 2012 Jun; 6(3):136-42. PubMed ID: 22890162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Scleroderma: from pathophysiology to novel therapeutic approaches.
    Hunzelmann N; Krieg T
    Exp Dermatol; 2010 May; 19(5):393-400. PubMed ID: 20507361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Scar wars: is TGFbeta the phantom menace in scleroderma?
    Leask A
    Arthritis Res Ther; 2006; 8(4):213. PubMed ID: 16774692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transforming growth factor beta as a therapeutic target in systemic sclerosis.
    Varga J; Pasche B
    Nat Rev Rheumatol; 2009 Apr; 5(4):200-6. PubMed ID: 19337284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy.
    Di Benedetto P; Liakouli V; Ruscitti P; Berardicurti O; Carubbi F; Panzera N; Di Bartolomeo S; Guggino G; Ciccia F; Triolo G; Cipriani P; Giacomelli R
    Arthritis Res Ther; 2018 Oct; 20(1):223. PubMed ID: 30285896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
    Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T
    Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma.
    Sonnylal S; Denton CP; Zheng B; Keene DR; He R; Adams HP; Vanpelt CS; Geng YJ; Deng JM; Behringer RR; de Crombrugghe B
    Arthritis Rheum; 2007 Jan; 56(1):334-44. PubMed ID: 17195237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines.
    Hasegawa M; Takehara K
    Semin Arthritis Rheum; 2012 Dec; 42(3):281-96. PubMed ID: 22542279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model.
    Chujo S; Shirasaki F; Kawara S; Inagaki Y; Kinbara T; Inaoki M; Takigawa M; Takehara K
    J Cell Physiol; 2005 May; 203(2):447-56. PubMed ID: 15605379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc?
    Abraham D
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v8-9. PubMed ID: 18784153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting interferons as a strategy for systemic sclerosis treatment.
    Ciechomska M; Skalska U
    Immunol Lett; 2018 Mar; 195():45-54. PubMed ID: 29106987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.